. 2022 Dec 30;21(2):854–863. doi: 10.1111/ajt.16348

TABLE 2.

Clinical management of patients

Patient	Type of care^a	Day of hospitalization post–symptom onset	Day of ICU transfer post–symptom onset	Type of O₂ therapy^b	Immuno suppression at onset^c	Immuno suppression level at diagnosis^d	Immuno suppression tapering^e	Immuno suppressants during COVID–19^f	Day of immunosuppressive regimen resumption^g	Time of recovery post–symptom onset (days)	Sampling days post–symptom onset^h
Kidney transplanted patients
KTX1	ICU	4	5	HFNC	Tac, MPA, Cs	Tac <2.2ⁱ MPA 500 mg x2	Tac↕, MPA↕	Tac <2.2 Cs 20 mg	24 (Tac MPA Cs 7.5 mg)	24	19^E–38^S–60^E,S
KTX2	ICU	10	16	HFNC	Tac, MPA, Cs	Tac 8 MPA 750 mg x2	Tac↕, MPA↕	dy 13 Tac 4.4 dy 16 Tac<2.2 Cs 20 mg	37 (Tac MPA Cs 10 mg)	37	31^E–53^E,S
KTX3	ICU	10	10	MV	Bel, MPA, Cs	Bel day –27 MPA 500 mg x2	Bel↕, MPA↕	Cs 20 mg	- (Cs 20 mg)	>80^j	26^E,S
KTX4	Hosp	7	—	Conv	Tac, MPA, Cs	Tac 4.7 MPA 750 mg x 2	MPA↕	Tac 4 Cs 20 mg	12 (Tac MPA Cs 7.5 mg)	12	42^E,S
KTX5	ICU	14	14	HFNC	Tac, MPA, Cs	Tac 6.1 MPA 500 mg x2	MPA↕	Tac 4 Cs 20 mg	40 (Tac MPA Cs 7.5 mg)	40	39^E,S–56^E,S
KTX6	Hosp	12	—	Conv	CsA, MPA	CsA 78 MPA 500 mg x 2	Csa↕, MPA↕	Cs 20 mg	25 (CsA MPA Cs 5 mg)	29	26^E,S
KTX7	Outpatient	—	—	—	Tac, MPA, Cs	Tac 6.6 MPA 500 mg x2	—	—	—	—	48^E,S
KTX8	Outpatient	—	—	—	Bel, MPA, Cs	Bel day 0 MPA 500 mg x2	—	—	—	—	37^E,S
KTX9	Outpatient	—	—	—	Bel, MPA, Cs	Bel day –5 MPA 500 mg x2	—	—	—	—	37^E,S
KTX10	Outpatient	—	—	—	Tac, MPA	Tac 9 MPA 750 mg x2	—	—	—	—	40^E,S
KTX11	Outpatient	—	—	—	Sir, Cs	Sir 10	—	—	—	—	49^E,S
Patients on hemodialysis
HD1	Outpatient	—	—	—	—	—	–	—	—	—	21^E,S–49^S
HD2	Hosp	4	—	Conv	—	—	–	—	—	16	17^E

^{^a}

ICU: intensive care unit; Hosp: patient hospitalized in conventional medical unit.

^{^b}

Conv: conventional oxygen therapy; HFNC: high-flow nasal canula; MV: mechanical ventilation.

^{^c}

Tac: tacrolimus; CsA: cyclosporine A; MPA: mycophenolic acid or mycophenolate mofetil; Cs: corticosteroids; Bel: belatacept. Sir: sirolimus.

^{^d}

Trough levels of tacrolimus (Tac), cyclosporine A (CsA), or sirolimus (Sir) in ng/ml, day of the last belatacept (Bel) infusion relative to symptoms onset, and mycophenolic acid or mycophenolate mofetil (MPA) dosage per day.

^{^e}

↕: withdrawal.

^{^f}

Trough levels of tacrolimus on the indicated day relative to symptoms onset and dosage of corticosteroids (Cs).

^{^g}

Immunosuppressive regimen at resumption in brackets. Immunosuppressants were not re-administered in patient KTX3.

^{^h}

The type of immunological assay performed at each sampling date is indicated as E: ELISPOT, S: serology. In bold, sampling done under or after reintroduction of a full immunosuppressive regimen.

^ⁱ

Low Tac trough levels maintained prior to and after COVID-19 due to Kaposi sarcoma in this patient.

^{^j}

Patient still hospitalized in ICU due to post-COVID-19 pulmonary function impairment.